LivaNova (LIVN) Upgraded to Overweight by KeyBanc
On January 26, Brett Fishbin from KeyBanc Capital Markets revised his rating on LivaNova PLC (NASDAQ:LIVN), from Sector Weight to Overweight.
Livanova Plc (LIVN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Paradice Investment Management David Paradice | 513,729 | $31,609,745 | +1% | 6.16% |
| 2. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $90.43 | 1,000 | $90,428.20 | 6,320 | 2021-11-10 | Filing | |
| $46.71 | 1,000 | $46,713.00 | 10,570 | 2020-06-16 | Filing | |
| $72.81 | 1,000 | $72,806.00 | 1,000 | 2019-05-02 | Filing | |
| $58.58 | 1,000 | $58,580.60 | 1,000 | 2017-05-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $53.94 | 250 | $13,485.00 | 6,232 | 2025-11-18 | Filing | |
| $56.50 | 1,500 | $84,750.00 | 9,028 | 2025-08-25 | Filing | |
| $50.99 | 1,250 | $63,737.50 | 7,522 | 2024-12-11 | Filing | |
| $46.58 | 1,500 | $69,870.00 | 8,772 | 2024-09-11 | Filing | |
| $61.09 | 2,045 | $124,920.87 | 27,534 | 2024-06-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,332,051 | $143,491,098 | 0% | |
| 2. | 547,554 | $33,690,998 | 0.01% | |
| 3. | 201,832 | $12,418,723 | 0.02% | |
| 4. | 176,223 | $10,843,001 | 0.01% | |
| 5. | 8,000,000 | $9,256,000 | 1.06% |
News See All
12 Best Medical Devices Stocks to Invest In According to Hedge Funds
It is challenging to identify segments within the markets that appear to be defensive plays, yet offer innovation potential.
LivaNova PLC (NASDAQ:LIVN) Q3 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to LivaNova plc Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
LivaNova PLC (NASDAQ:LIVN) Q2 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the LivaNova PLC Second Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
Jefferies Maintained a Buy Rating on LivaNova PLC (LIVN)
LivaNova PLC (NASDAQ:LIVN) is one of the Best Undervalued UK Stocks to Buy According to Analysts. On June 6, Jefferies analyst Matthew Taylor maintained a Buy rating on LivaNova PLC (NASDAQ:LIVN) with...
12 Best Undervalued UK Stocks to Buy According to Analysts
On July 14, Equity released its UK outlook for Q3 2025, noting that the market entered the third quarter at a turning point with steady growth and IMF upgrades.
Jefferies Reaffirms ‘Buy’ Rating on LivaNova PLC (LIVN) with $79 PT
On June 5, 2025, LivaNova PLC (NASDAQ:LIVN) reported the completion of its landmark CORE-VNS study. More than 800 real-world patients with drug-resistant epilepsy were tracked under this study.
10 Most Undervalued Foreign Stocks to Buy According to Analysts
The dominance of U.S. stocks within the investment landscape has existed for years, with the S&P 500 index leading with an impressive 14.20% annualized return over the last 15 years.
LivaNova's VNS Therapy Shows Sustained Effectiveness in Drug-Resistant Epilepsy
LivaNova (NASDAQ:LIVN) is one of the best mid cap pharma stocks to buy.
10 Best Mid Cap Pharma Stocks to Buy
On July 14, Emily Field, the head of European pharma research at Barclays, appeared on CNBC to discuss which drug makers would be most impacted by 30% US tariffs on EU imports.